Enoxaparin is used in the treatment and prevention of Blood clots. It prevents the formation of blood clots in the legs, lungs, brain or heart.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Intravas 40mg Injection 0.4 ml contains Enoxaparin, a low molecular weight heparin (LMWH) that treats harmful blood clots in the blood. It can also prevent blood clots caused by various medical conditions such as unstable angina, post-operation or prolonged bed rest, after a heart attack, and in the tubes of dialysis machines. Intravas 40mg Injection 0.4 ml works by halting the growth of existing blood clots, allowing the body to break them down and preventing harm. It also prevents the formation of new blood clots in the bloodstream.
Avoid consumption of alcohol before receiving Intravas 40mg Injection.
Intravas 40mg Injection is not recommended for use in pregnancy. Your doctor will weigh the benefits and risks before prescribing this medicine to you.
Intravas 40mg Injection is not recommended for use in breastfeeding. Your doctor will weigh the benefits and risks before prescribing this medicine to you.
Intravas 40mg Injection does not affect your ability to drive or operate machinery. However, do not drive or handle any heavy tools or machines if your ability is affected by Intravas 40mg Injection.
Intravas 40mg Injection may increase the risk of bleeding if you have kidney problems. Your doctor may adjust the dose of this medicine or prescribe a suitable alternative based on your condition.
Intravas 40mg Injection is known to increase the levels of liver enzymes causing serious complications. Therefore, it should be used with caution if you have liver problems.
Intravas 40mg Injection works by interfering with the normal clotting process and decreasing the clot-forming ability of the blood.
Enoxaparin is indicated for:
Enoxaparin Sodium is a low molecular weight heparin with high anti-Xa activity and low anti-IIa or antithrombin activity. It does not increase bleeding time at the dosages used for various indications. At prophylactic doses, it does not significantly alter activated Partial Thromboplastin Time (aPTT). It does not affect platelet aggregation or the binding of fibrinogen to platelets. Enoxaparin Sodium is primarily metabolized in the liver.
For the treatment of deep vein thrombosis, with or without pulmonary embolism, the recommended dose of Enoxaparin Sodium is either 100 anti-Xa lU/kg twice daily for 10 days or 150 anti-Xa lU/kg once daily for 10 days. Oral anticoagulant therapy should be initiated as appropriate, and Enoxaparin Sodium treatment should be continued until a therapeutic anticoagulant effect has been achieved.
For the treatment of unstable angina and non-Q-wave myocardial infarction, Enoxaparin Sodium is administered subcutaneously at 100 anti-Xa lU/kg twice daily for 2-8 days, along with oral aspirin (100 to 325 mg once daily). Treatment with Enoxaparin Sodium should be prescribed for a minimum of 2 days and continued until clinical stabilization.
For the prevention of thrombus formation in extracorporeal circulation during hemodialysis, the recommended dose is 100 anti-Xa lU/kg. For patients at a high risk of hemorrhage, the dose should be reduced to 50 anti-Xa lU/kg for double vascular access or 75 anti-Xa lU/kg for single vascular access. Enoxaparin Sodium should be introduced into the arterial line of the circuit at the beginning of the dialysis session.
For prophylaxis of venous thromboembolic disease in surgical patients, the dose varies depending on the type of surgery. For general surgery with a moderate risk of thromboembolism, the recommended dose is 2000 anti-Xa IU (0.2 ml) or 4000 anti-Xa IU (0.4 ml) once daily for 7 to 10 days. For orthopedic surgery with a high risk of thromboembolism, the recommended dose is 4000 anti-Xa IU (0.4 ml) once daily for 7 to 10 days. The first injection should be given before the surgical procedure as per the time specified.
For prophylaxis of venous thromboembolic disease in medical patients, the recommended dose is 4000 anti-Xa IU (0.4 ml) once daily for 6-14 days.
It's important to note that Intravas 40mg Injection should be administered by a doctor or a nurse either intravenously or subcutaneously. In some cases, self-administration may be advised by the physician, and in such cases, the patient should carefully follow the instructions given by the doctor. The appropriate dose and duration of therapy will be determined by your doctor based on your age, body weight, and medical condition.
Intravas 40mg Injection 0.4 ml may interact with several drugs, such as painkillers, blood thinners, drugs used to treat asthma and medications that increase potassium levels in the blood. It is also advised to avoid consuming alcoholic beverages while using this medication.
In addition, Intravas 40mg Injection 0.4 ml may have interactions with various disease conditions, including hemophilia, liver disease, peptic ulcer disease, retinopathy, subacute bacterial endocarditis, active bleeding, hypertension, renal dysfunction, thrombocytopenia, prematurity, and kidney disease. It is important to inform your doctor about any existing medical conditions before using this medication.
Patients who have previously been allergic to Enoxaparin Sodium, heparin, or other low molecular weight heparins. Active major bleeding and conditions that increase the risk of uncontrolled hemorrhage, such as recent hemorrhagic stroke.
Enoxaparin Sodium is classified as Pregnancy Category B, indicating that there is no evidence of it crossing the placental barrier in humans. However, since there are no sufficient and well-controlled studies in pregnant women, it should be used during pregnancy only if clearly needed. Pregnant women with mechanical prosthetic heart valves may be at a higher risk for thromboembolism.
It is not known whether Enoxaparin is excreted in human milk. Considering the potential for serious adverse reactions in nursing infants due to the excretion of many drugs in human milk, a decision should be made whether to discontinue nursing or suspend Enoxaparin, taking into account the importance of Enoxaparin to the mother and the known benefits of nursing.
Patients should inform their doctor if they are on active treatment with Intravas 40mg Injection 0.4 ml before any surgery is scheduled. If they have any known allergies to Intravas 40mg Injection or any other medicines, they should inform their doctor. For pregnant or breastfeeding individuals, it is important to inform the doctor before using Intravas 40mg Injection 0.4 ml.
Before using Intravas 40mg Injection 0.4 ml, patients should disclose any pre-existing medical conditions, such as stomach ulcer, recent brain/eye/spine surgery, recent bleeding stroke, diabetes, high blood pressure, recent stroke, or kidney/liver disorders. Additionally, it is important to inform the doctor if they are underweight or overweight, or have high levels of potassium in their blood.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.